Postvaccination SARS‐CoV‐2 Alpha (B.1.1.7) lineage infection among healthcare workers on the background of IgG antibodies

Abstract

Postvaccination SARS-CoV-2 Alpha (B.1.1.7) lineage infection among healthcare workers on the background of IgG antibodies Like most vaccines, the effectiveness of COVID-19 vaccines developed so far is not 100% and a small percentage of fully vaccinated individuals still develop symptomatic or asymptomatic SARS-CoV-2 infections. 1 In addition, the emerging of novel mutations is likely to help the virus evade vaccines especially in regions with low vaccination coverage. 2 In this study, we analyzed SARS-CoV-2 infections in two healthcare workers (HCWs) fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) and subsequently diagnosed with postvaccination SARS-CoV-2 on a background of IgG antibodies.Epidemiological and clinical data including, symptoms initial analysis and observations were obtained from the National electronic system for COVID-19 (Table 1).Blood samples of the HCWs were tested for anti-SARS-CoV-2 IgG antibodies. The analysis was performed using two different serological tests: The VIDAS ® SARS-COV-2 IgG Enzyme-Linked Fluorescent Assay (Biomerieux) and SARS -CoV-2 II Quant Abbott Architect (Abbott).Viral RNA was extracted from nasal swabs using an ExiPrep 48 Viral DNA/RNA Kit (Bioneer) following the manufacturer's instructions. Real-time PCR was performed using GeneFinder™ COVID-19 Plus RealAmp Kit (OSANG Healthcare Co., Ltd.).Whole-genome next-generation sequencing (NGS) of SARS-CoV-2 was performed by using a modified ARTIC v3 tailed amplicon method and Illumina MiSeq v2 reagent kit with 500 cycles (Illumina).

Students’ Attitudes toward COVID-19 Vaccination: An Inter-University Study from Bulgaria

“…Bulgaria and the Bulgarian public health system were also in a difficult situation. In this regard, several studies on SARS-CoV-2 infection had been conducted in our country, including: a seroepidemiological survey [ 10 ]; research on clinical characteristics of patients with COVID-19 [ 11 , 12 ]; studies of immune response to SARS-CoV-2 vaccines [ 13 , 14 , 15 ]; research into adverse events of COVID-19 vaccines [ 16 ]; studies dealing with inconclusive SARS-CoV-2 PCR samples [ 17 ]; and studies of liver involvement in children with COVID-19 and multisystem inflammatory syndrome [ 18 ]. The Bulgarian vaccination process started on 26 December 2020.…”

Initial introduction and spread of the SARS‐CoV‐2 AY.4.2.1 Delta variant in Bulgaria, a genomic insight

“…1 Since the emergence of SARS-CoV-2, many variants of the virus have branched off, some of which are of particular importance due to their potential for increased transmissibility, virulence, or reduced vaccine effectiveness. 2,3 In late 2020, the emergence of variants that posed an increased risk to global public health prompted the characterization of specific variants of concern (VOCs), variants of interest (VOIs), and variant under investigation (VUI) so as to prioritize global monitoring and research, and ultimately to inform the ongoing response to the COVID-19 pandemic. WHO provides regular updates on currently circulating VOCs, and as of May 25, 2022, these are Delta (B.1.617.2) and Omicron (B.1.1.529).…”

“…The COVID‐19 pandemic was caused by the emerging coronavirus SARS‐CoV‐2 in 2019, which led to an unprecedented pandemic related to the challenges facing national health systems, social systems, and the global economy 1 . Since the emergence of SARS‐CoV‐2, many variants of the virus have branched off, some of which are of particular importance due to their potential for increased transmissibility, virulence, or reduced vaccine effectiveness 2,3 . In late 2020, the emergence of variants that posed an increased risk to global public health prompted the characterization of specific variants of concern (VOCs), variants of interest (VOIs), and variant under investigation (VUI) so as to prioritize global monitoring and research, and ultimately to inform the ongoing response to the COVID‐19 pandemic.…”

Genomic Epidemiology and Lineage Dynamics of SARS-CoV-2 in Bulgaria: Insights from a Three-Year Pandemic Analysis

“…While Bulgaria initially implemented control policies at the onset of the pandemic, the subsequent waves of infection posed significant challenges, leading to one of the world’s highest COVID-19 mortality rates. The low vaccination coverage in the country played a critical role in this trend, with immunization gaps allowing the virus to spread more effectively within susceptible populations [ 25 ]. The spread of recombinant variants in 2023 is an interesting phenomenon related to the evolution of SARS-CoV-2, which should be monitored with caution as the pandemic progresses [ 26 ].…”